Protalix BioTherapeutics, Inc. Stock TEL AVIV STOCK EXCHANGE
Equities
PLX
US74365A3095
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
732.5 ILa | -.--% | +3.29% | +69.68% |
06-26 | Transcript : Protalix BioTherapeutics, Inc. - Analyst/Investor Day | |
05-10 | Transcript : Protalix BioTherapeutics, Inc., Q1 2024 Earnings Call, May 10, 2024 |
Sales 2024 * | 52.7M 19.84B 72.08M | Sales 2025 * | 101M 38.18B 139M | Capitalization | 85.78M 32.3B 117M |
---|---|---|---|---|---|
Net income 2024 * | 8M 3.01B 10.94M | Net income 2025 * | 54M 20.33B 73.86M | EV / Sales 2024 * | 1.63 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.85 x |
P/E ratio 2024 * |
9.75
x | P/E ratio 2025 * |
1.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.42% |
Latest transcript on Protalix BioTherapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- PLX Stock
- PLX Stock